Singapore Tuberculosis Diagnostics Market Industry Trends and Forecast to 2034: Segmented by (Test, Setting, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
Market Dashboard
Singapore · 2024–2034 · placeholder estimates
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the
full report.
Estimate 2024$2.7 MnPlaceholder estimate
Estimate 2025$2.8 Mn0.1% of the global market
Projected 2034$4.9 Mn 73.3%Adds $2.1 Mn over 9 forecast years
CAGR 2025–20346.3%Faster than 9% of 173 Medical Devices markets here
2 in SingaporeSource: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Singapore. Retrieved 12 Nov 2026.
Formats
PDF, PPTX, XLSX
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
The Singapore Tuberculosis Diagnostics Market Analysis Executive Summary
Tuberculosis diagnostics find TB infection and disease using skin tests, blood tests, molecular tests and chest X-ray reading.
Key segments of the tuberculosis Diagnostics market include test (Molecular Tests, Interferon Gamma Release Assays and Skin Tests) and setting (Hospitals, TB Programs and Point of Care).
Singapore Tuberculosis Diagnostics market size, 2024–2034. Placeholder estimates; researched figures come with the full report. Source: Acuitas Health Analytics.
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the tuberculosis Diagnostics market.
Opportunity
Home testing, connected devices that send results to doctors and multiplex tests that check many conditions at once give the tuberculosis Diagnostics market room to grow, especially in emerging markets.
Market Restraints
Pricing pressure, uneven reimbursement for new tests, regulatory approval times and the need for skilled lab staff hold back the tuberculosis Diagnostics market.
Competitive Landscape for Tuberculosis Diagnostics Market in Singapore
The tuberculosis Diagnostics market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Healthcare Policies and Regulatory Landscape for Tuberculosis Diagnostics Market in Singapore
Tuberculosis Diagnostics in Singapore: rules, payment and research
Medical devices must be registered with the Health Sciences Authority (HSA), except low-risk Class A devices.[1] MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts.[2] ClinicalTrials.gov lists 2 studies on Tuberculosis Diagnostics that are recruiting, active or about to start in Singapore.[3] Tuberculosis new cases: 43 per 100,000 people in 2024, the latest WHO figure for Singapore.[4]
Medical device rules, such as the US FDA 510(k) and PMA pathways and the EU Medical Device Regulation, govern how tuberculosis Diagnostics products are approved and monitored. Reimbursement codes and hospital purchasing policies decide how widely they are used in Singapore.
2.2 Market Size, Growth Prospects and Key findings
3 Market Dynamics
3.1 Market Growth Drivers Analysis
3.2 Market Restraints Analysis
4 Market Segmentation
4.1 By Test
4.2 By Setting
4.3 By End User
5 By Market Share
5.1 Market Analysis, Insights and Forecast – By Revenue
6 Competitive Landscape
6.1 Major Top Market Players Products in Pipeline
6.2 R&D Initiatives
6.3 Notable recent Deals
6.3.1 Strategic Divestments
6.3.2 Mergers & Acquisitions
6.3.3 Partnerships
6.3.4 Joint Ventures
7 Key Company Profiles
7.1 Cepheid (Danaher)
7.2 QIAGEN
7.3 Molbio Diagnostics
7.4 Qure.ai
7.5 Revvity
8 Healthcare Policies and Regulatory Landscape
8.1 Policy changes and Reimbursement scenario
8.2 Government Initiatives / Intervention programs
The tuberculosis Diagnostics market can be segmented based on various criteria, including test, setting and end user. Here's a breakdown of the market segmentation
Other companies that free public records show in this market: trials they lead, US approvals and WHO prequalification. They are not part of our key players research. Each count opens its source.
Also active in this area, from free public records
Source: ClinicalTrials.gov, Active studies (recruiting, about to start or running) each company leads, found with this market's trial search, worldwide. Retrieved 13 Nov 2026.
Source: WHO Prequalification, Vaccines, tests and medicines on the WHO prequalified lists that match this market. Retrieved 13 Nov 2026.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Tuberculosis Diagnostics right now, from free public sources.
How big is the Tuberculosis Diagnostics market in Singapore?
Placeholder estimate: about $2.8 Mn in 2025, rising to about $4.9 Mn by 2034. These are early estimates, not researched figures; the researched values come with the full report.
How fast is the Tuberculosis Diagnostics market in Singapore growing?
Placeholder estimate: about 6.3% a year (CAGR, 2025–2034). The researched growth rate comes with the full report.
What segments does the Tuberculosis Diagnostics market report cover?
The report splits the market by test (Molecular Tests, Interferon Gamma Release Assays, Skin Tests, Sputum Smear and more), setting (Hospitals, TB Programs, Point of Care) and end user (Hospitals, Ambulatory Surgical Centers, Diagnostic Centers, Home Care Settings).
Who are the key players in the Tuberculosis Diagnostics market?
Key players include Cepheid, Qiagen N.V., Molbio Diagnostics, Qure.ai and Revvity.
What is driving the Tuberculosis Diagnostics market?
Demand for earlier and faster diagnosis, growth of testing outside hospitals, new molecular technologies and the shift to preventive care are driving the tuberculosis Diagnostics market.
Who regulates Tuberculosis Diagnostics in Singapore?
Medical devices must be registered with the Health Sciences Authority (HSA), except low-risk Class A devices. Source: Health Sciences Authority. Checked 14 Nov 2026.
How is healthcare paid for in Singapore?
MediShield Life gives basic health insurance to all citizens and permanent residents, alongside MediSave savings accounts. Source: CPF Board, MediShield Life. Checked 14 Nov 2026.
How many clinical trials on Tuberculosis Diagnostics are running in Singapore?
2 studies are recruiting, active or about to start in Singapore, according to ClinicalTrials.gov. Source: ClinicalTrials.gov, Studies recruiting, active or not yet recruiting, in Singapore. Retrieved 12 Nov 2026.
What does WHO report for Singapore?
Tuberculosis new cases: 43 per 100,000 people in 2024, the latest WHO figure. Source: WHO Global Health Observatory, Tuberculosis new cases (per 100,000 people). Retrieved 15 Nov 2026.
How many people in Singapore are 65 or older?
14.2% of people were 65 or older in 2025. Source: World Bank Open Data, Population ages 65 and above (% of total population), from UN population estimates. Retrieved 15 Nov 2026.
Singapore 
China
India
US
Canada
Japan
Germany
France
UK
Italy
Ecuador
Spain
Brazil
Saudi Arabia
Mexico
Australia
Russia
New Zealand
South Africa
UAE
Egypt
Philippines
Hong Kong
Malaysia
Thailand
Kenya
Roche